New hope for lung cancer patients who failed targeted therapy: phase 3 trial launched
NCT ID NCT06671379
First seen Mar 20, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This phase 3 study compares a new drug, SHR-A2009, with standard platinum-based chemotherapy in about 500 adults with advanced EGFR-mutated non-small cell lung cancer that has worsened after EGFR-targeted therapy. The main goal is to see if SHR-A2009 can delay cancer growth better than chemo. Participants must have measurable tumors and good organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.